Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.

Authors: Alex Chehrazi-Raffle, Robert J. Motzer, Katy Beckermann, Philippe Barthelemy, Roberto Iacovelli, Sheik Emambux, Javier Molina Cerrillomd, Benjamin Garmezy, Pedro C. Barata, Rana R. McKay, Hans J. Hammers, Daniel Yick Chin Heng, Bo Jin, Claudia Lebedinsky, Edgar E. Braendle, Bradley Alexander McGregor, Laurence Albiges, Toni K. Choueiri

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.4540

Source: Full article

---

Abstract

4540